financetom
Business
financetom
/
Business
/
Indigo Paints sees softening in raw material costs; expects margin improvement in Q4
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Indigo Paints sees softening in raw material costs; expects margin improvement in Q4
Feb 14, 2022 2:26 AM

Indigo Paints came out with its Q3 earnings. The company reported a 29.9 percent year-on-year (YoY) increase in net profit at Rs 24.3 crore for the third quarter ended December 31, 2021. In the corresponding quarter last year, the company had posted a net profit of Rs 18.7 crore. Its total revenue during the quarter rose by 26.6 percent YoY to Rs 265.4 crore from Rs 209.6 crore in the year-ago quarter.

In an interview with CNBC-TV18, Hemant Jalan, CMD, Indigo Paints, discussed the Q3 performance and outlook.

Speaking about margin, he shared that it has contracted across the industry. However, he mentioned that margin has improved on a quarter-on-quarter (QoQ) basis for the company and going ahead, he expects it to further improve in Q4 as there has been some softening in raw material costs as well.

"Margin contraction has happened across the paint industry, because of a huge pressure on raw material pricing. But if you look at the margins from the preceding quarter, we have shown a healthy rise and much more rise is expected in the next quarter," he said.

He added, "We have seen a slight softening of some of the raw materials during the last few months."

Also Read:

Indigo Paints Q3 results: Net profit rises 30% YoY to Rs Rs 24.3 crore, revenue up 26.6% to Rs 265.4 crore

Affirming that the company is not facing any stress for its products from the rural side, he explained that Q4 has in fact, always been the strongest quarter for the company seasonally.

"I don't see any stress in the rural market as far as paints are concerned. We have not noticed any slowdown or any significant difference in the demand uptick between the rural areas and the urban areas," he mentioned.

He further said, "Demand is fairly decent across all categories of cities and towns. For our company, Q4 has traditionally been the strongest quarter, both in terms of sales growth as well as in terms of EBITDA margins."

Also Read: Brent could push through to $100/bbl: Fat Prophets

On price hikes, he mentioned, "I am not anticipating any further price hikes in the foreseeable future."

On volume growth, Jalan said that emulsion category has seen a surge of 16 percent.

"We have to look at volume growth in various sub categories of the paint industry to make any meaningful conclusion out of them. But the most important category, which is the emulsion category, we have had a good growth in volume in this quarter in excess of 16 percent," he said.

Watch the video for the full interview.

Catch all stock market updates here

First Published:Feb 14, 2022 11:26 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sputnik V could be EPS dilutive for Dr Reddy’s: Sanford Bernstein’s Nithya Balasubramanian
Sputnik V could be EPS dilutive for Dr Reddy’s: Sanford Bernstein’s Nithya Balasubramanian
Jun 16, 2021
Sanford Bernstein has an outperform rating on Dr Reddys Laboratories (DRL). Nithya Balasubramanian, Director at Sanford Bernstein, believes that the Sputnik V COVID-19 vaccine could be EPS dilutive for Dr Reddy’s as of now.
Warning letter for Lupin’s Somerset plant disappointing: Sanford Bernstein’s Nithya Balasubramanian
Warning letter for Lupin’s Somerset plant disappointing: Sanford Bernstein’s Nithya Balasubramanian
Jun 16, 2021
Drug major Lupin has received a warning letter from the US health regulator for its Somerset, New Jersey facility. The US FDA had inspected the site from September 10, 2020 to November 5, 2020. Nithya Balasubramanian, Director at Sanford Bernstein expressed her disappointment at this.
KIMS IPO: Will use Rs 150 cr out of Rs 200 cr to repay debt, says management
KIMS IPO: Will use Rs 150 cr out of Rs 200 cr to repay debt, says management
Jun 16, 2021
Krishna Institute of Medical Sciences’ (KIMS) IPO has opened for subscription n Wednesday (June 16), and will close on June 18. The IPO size is Rs 2,120 to Rs 2,144 crore and the price band has been set at Rs 815-825. Dr Bhaskara Rao Bollineni, MD of KIMS, said that the company will use the money raised to reduce debt.
Dodla Dairy IPO: Mgmt says focused on value-added products; aims to hit pre-COVID capacity soon
Dodla Dairy IPO: Mgmt says focused on value-added products; aims to hit pre-COVID capacity soon
Jun 16, 2021
Integrated milk products company Dodla Dairy's Rs 520 crore initial public offering (IPO) issue is now open for subscription from Wednesday. To understand the prospects of the company post the IPO issue and the outlook for the business going ahead, CNBC-TV18 spoke to the Managing Director of the company, Sunil Reddy Dodla.
Copyright 2023-2026 - www.financetom.com All Rights Reserved